1244041-71-1

Basic information

• Product Name: (6-BroMo-benzothiazol-2-yl)-carbaMic acid tert-butyl ester
• Synonyms: (6-BroMo-benzothiazol-2-yl)-carbaMic acid tert-butyl ester;tert-butyl 6-bromobenzo[d]thiazol-2-ylcarbamate
• CAS NO: 1244041-71-1
• Molecular Formula: C₁₂H₁₃BrN₂O₂S
• Molecular Weight: 329.21282
• EINECS: -0
• Mol File: 1244041-71-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (6-BroMo-benzothiazol-2-yl)-carbaMic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (6-BroMo-benzothiazol-2-yl)-carbaMic acid tert-butyl ester(1244041-71-1)
• EPA Substance Registry System: (6-BroMo-benzothiazol-2-yl)-carbaMic acid tert-butyl ester(1244041-71-1)

Safety Data

• Hazardous Substances Data: 1244041-71-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(6-Bromo-benzothiazol-2-yl)-carbamic acid tert-butyl ester is used as a building block for the synthesis of various pharmaceuticals due to its unique chemical structure and stability. Its presence in the molecule can contribute to the development of new drugs with potential therapeutic applications.
Used in Material Science:
(6-Bromo-benzothiazol-2-yl)-carbamic acid tert-butyl ester is used as a component in the development of new materials due to its chemical properties. Its potential applications in this field may include the creation of novel materials with specific properties for various uses, such as in electronics, coatings, or other advanced technologies.
Used in Chemical Research:
(6-Bromo-benzothiazol-2-yl)-carbamic acid tert-butyl ester is used as a research compound for studying the properties and reactions of carbamic acid esters and benzothiazole derivatives. Its unique structure allows chemists to explore new reaction pathways and develop innovative synthetic methods for creating complex organic molecules.

Upstream product

• 15864-32-1 2-amino-6-bromobenzothiazole 
• 24424-99-5 di-tert-butyl dicarbonate 
• 53218-26-1 6-bromo-1,3-benzothiazole 
• 73210-14-7 N-chloro-N-sodio-tert-butylcarbamate 
• 4248-19-5 tert-butyl carbazate 
• 769069-45-6 tert-butyl N-chlorocarbamate 

Downstream Products

• 73458-38-5 6-phenylbenzo[d]thiazole-2-amine 

Relevant articles and documents

Discovery of potent, selective small molecule inhibitors of α-subtype of type III phosphatidylinositol-4-kinase (PI4KIIIα)

Abstract The discovery and optimisation of novel, potent and selective small molecule inhibitors of the α-isoform of type III phosphatidylinositol-4-kinase (PI4Kα) are described. Lead compounds show cellular activity consistent with their PI4Kα potency inhibiting the accumulation of IP1 after PDGF stimulation and reducing cellular PIP, PIP2 and PIP3 levels. Hence, these compounds are useful in vitro tools to delineate the complex biological pathways involved in signalling through PI4Kα.

BROAD SPECTRUM ANTI-CANCER COMPOUNDS

Described herein, inter alia, are compounds for treating cancer and methods of use. This disclosure features chemical entities (e.g., small hairpin RNAs (shRNAs), micro RNA (miRNAs), small interfering RNA (siRNAs), small molecule inhibitors, antisense nucleic acids, peptides, viruses, CRISPR-sgRNAs, or combinations thereof) that inhibit one or more of m6A writers (e.g., methyltransferase like 3 (Mettl3 or MT-A70) or methyltransferase like-14 (Mettl14)), m6Am writers (e.g., phosphorylated CTD interacting factor I (PCIF 1), or Mettl3/14), m6A erasers (e.g., fat-mass and obesity-associated protein (FTO) or ALKB homolog 5 (ALKBH5)), m6Am erasers (e.g., FTO), m6A readers (e.g., YTH domain-containing family proteins (YTHs)), YTF domain family member 1 (YTHDF 1), YTF domain family member 2 (YTHDF 2), YTF domain family member 3 (YTHDF 3), or tyrosine-protein phosphatase non-receptor type 2 (PTPN2).

HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND METHOD USING THE SAME

The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosis. Formula (I) is shown below:

TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.

(NHC)Cu-Catalyzed Mild C-H Amidation of (Hetero)arenes with Deprotectable Carbamates: Scope and Mechanistic Studies

Primary arylamines are an important unit broadly found in synthetic, biological, and materials science. Herein we describe the development of a (NHC)Cu system that mediates a direct C-H amidation of (hetero)arenes by using N-chlorocarbamates or their sodio derivatives as the practical amino sources. A facile stoichiometric reaction of reactive copper-aryl intermediates with the amidating reagent led us to isolate key copper arylcarbamate species with the formation of a C-N bond. The use of tBuONa base made this transformation catalytic under mild conditions. The present (NHC)Cu-catalyzed C-H amidation works efficiently and selectively on a large scale over a range of arenes including polyfluorobenzenes, azoles, and quinoline N-oxides. Deprotection of the newly installed carbamate groups such as Boc and Cbz was readily performed to afford the corresponding primary arylamines.

FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE

The invention relates to compounds of formula (I) for the regulation of phosphoinositides 3-kinases activity and related diseases.

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

The present invention relates to niacin receptor agonists of formula: (I); as well as pharmaceutically acceptable salts and solvates. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, VLDL and triglycerides, and raising HDL levels. Pharmaceutical compositions and methods of treatment are also included.